WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010123569) IMMUNONANOTHERAPEUTICS PROVIDING A TH1-BIASED RESPONSE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/123569    International Application No.:    PCT/US2010/001203
Publication Date: 28.10.2010 International Filing Date: 21.04.2010
IPC:
A61K 47/48 (2006.01), A61P 39/00 (2006.01)
Applicants: SELECTA BIOSCIENCES, INC. [US/US]; 480 Arsenal Street Building One Watertown, MA 02472 (US) (For All Designated States Except US).
LIPFORD, Grayson, B. [US/US]; (US) (For US Only).
BRATZLER, Robert, L. [US/US]; (US) (For US Only)
Inventors: LIPFORD, Grayson, B.; (US).
BRATZLER, Robert, L.; (US)
Agent: VATLAND, Janice, A.; Wolf, Greenfield & Sacks, P.C. 600 Atlantic Avenue Boston, MA 02210-2206 (US)
Priority Data:
61/214,229 21.04.2009 US
Title (EN) IMMUNONANOTHERAPEUTICS PROVIDING A TH1-BIASED RESPONSE
(FR) COMPOSÉS IMMUNONANOTHÉRAPEUTIQUES FOURNISSANT UNE RÉPONSE À MÉDIATION PAR TH1
Abstract: front page image
(EN)Disclosed are synthetic nanocarrier compositions, and related methods, for treating diseases in which generating a Th1 -biased immune response is desirable. In an aspect, the invention relates to a composition for treatment of a condition comprising: synthetic nanocarriers comprising (1) an immunofeature surface, an (2) a Th1 biasing immunostimulatory agent coupled to the synthetic nanocamers; and a pharmaceutically acceptable excipient; wherein the immunofeature surface does not comprise antigen that is relevant to treatment of the condition in an amount sufficient to provoke an adaptive immune response to the antigen that is relevant to treatment of the condition. In another aspect, the invention relates to a method comprising: identifying a subject suffering from a condition; providing a composition that comprises synthetic nanocarriers that comprise (1) an APC targeting feature, and (2) a Th1 biasing immunostimulatory agent coupled to the synthetic nanocarriers; and a pharmaceutically acceptable excipient; and administering the composition to the subject; wherein the administration of the composition does not further comprise co-administration of an antigen that is relevant to treatment of the condition. In yet another aspect, the invention relates to a method comprising: providing a composition comprising synthetic nanocarriers that comprise a Th1 biasing immunostimulatory agent and an APC targeting feature; administering the composition to a subject; and administering an antigen to the subject to which a Th1 biased response is desired at a time different from administration of the composition to the subject; wherein administration of the antigen comprises passive administration or active administration.
(FR)L'invention porte sur des compositions de nanosupport synthétiques et sur des procédés associés pour traiter des maladies dans lesquelles il est désirable de générer une réponse immunitaire à médiation par Th1.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)